相关临床试验
58
15 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1898
进行中（未招募）
2
3.5%
已完成
21
36.2%
Enrolling By Invitation
1
1.7%
尚未招募
12
20.7%
招募中
14
24.1%
终止
2
3.5%
Unknown
6
10.3%
暂无批准数据
- The £20 million Liverpool Accelerate Laboratory, the first facility of its kind in the UK, has officially opened at the Liverpool School of Tropical Medicine. - The facility combines advanced robotics, artificial intelligence and human organoid technology to speed up drug and vaccine development while reducing reliance on animal testing. - Built to Containment Level 3 (CL3) and Schedule Five biohazard security standards, the steel-clad lab enables safe, automated work with dangerous pathogens such as salmonella and TB. - The laboratory is forecast to generate £40 million in investment within its first three years and is scheduled to become fully operational in 2027.
- A new study in The Lancet Microbe calls for integrating female genital schistosomiasis (FGS) screening into existing sexual and reproductive health services across sub-Saharan Africa. - FGS, caused by Schistosoma haematobium, affects at least 40 million women globally and may increase vulnerability to HIV and HPV through chronic inflammation and tissue damage. - Researchers from LSTM, MLW, and LSHTM propose combined HPV–FGS testing from single genital samples, improved healthcare worker training, and AI-supported diagnostic tools. - The emergence of zoonotic and hybrid schistosome species in genital samples raises new concerns about diagnosis, treatment effectiveness, and the need for One Health approaches.
- A study published in Thorax found 574 people in England were diagnosed with TB only after death between 2010 and 2022, averaging nearly one person per week. - British-born older men, children under four, and those with substance misuse history were disproportionately affected by postmortem TB diagnosis. - England's TB rate reached 9.4 per 100,000 in 2024, approaching the WHO low-incidence threshold of 10 cases per 100,000. - Researchers call for postmortem TB diagnosis to be treated as a "never event" triggering root cause analysis to prevent future deaths.
- Medicines for Malaria Venture (MMV), the world's leading antimalarial product development partnership, has joined the Infection Innovation Consortium (iiCON) as a core partner to accelerate infectious disease research. - The collaboration will integrate MMV's AI/machine learning drug design tools and global screening networks with iiCON's platforms for natural product screening, antimicrobial resistance research, and organoid-based drug discovery. - iiCON has secured over £251 million in investment since 2020 and has supported 36 new products to market, with over 5 billion units of life-saving treatments reaching global communities. - The partnership aims to leverage synergies between MMV's antimalarial expertise and iiCON's broader infectious disease platforms to develop new antibiotics, antivirals, antiparasitics, and antifungals.
- The World Health Organization has issued its first recommendation for a new malaria vector control tool in over 40 years, endorsing spatial repellents that provide an average 56% protection against mosquito bites. - Clinical trials funded by Unitaid demonstrated that spatial repellents reduced malaria cases by one-third when used alongside insecticide-treated nets, leading to WHO's conditional recommendation in August. - Three spatial repellent products are now available, with Guardian offering up to one year of protection, addressing critical gaps as traditional vector control methods face declining effectiveness due to insecticide resistance. - Unitaid has launched an $18 million investment to expand evidence for spatial repellents as standalone interventions, particularly important as global funding cuts make layering multiple interventions increasingly unaffordable.
- Scientists have developed a groundbreaking antivenom using antibodies from Tim Friede, who voluntarily endured over 200 snake bites and 700 venom injections over nearly 20 years. - The experimental treatment showed unprecedented effectiveness in mouse trials, providing full protection against 13 deadly snake species and partial protection against six others. - Researchers from Centivax isolated two powerful antibodies from Friede's blood, creating a therapeutic cocktail that could potentially replace traditional antivenoms and save thousands of lives annually.
- Liverpool School of Tropical Medicine receives £10M funding to establish AI-powered robotic Containment Level 3 laboratories for accelerating development of treatments for high-risk infectious diseases. - The new facility, supported by the Infection Innovation Consortium (iiCON), will enhance human organoid research and is forecast to generate £40M in investment within three years, creating high-value jobs. - This combined £20M initiative, including additional funding from UKRI and the Wolfson Foundation, strengthens Liverpool City Region's position as a global hub for infection innovation and health science research.
- Researchers have discovered that nitisinone, a drug used to treat rare genetic disorders, makes human blood toxic to mosquitoes that transmit malaria, offering a potential new control strategy. - The study published in Science Translational Medicine demonstrated nitisinone remains active in bloodstream longer than current alternative ivermectin and effectively kills mosquitoes of all ages, including those resistant to traditional insecticides. - Nitisinone works by blocking the HPPD enzyme in mosquitoes, preventing them from digesting blood and causing rapid paralysis and death, potentially providing an alternative in regions with ivermectin resistance.
